|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 28745 |
FusionGeneSummary for PRKCE_QPCT |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PRKCE_QPCT | Fusion gene ID: 28745 | Hgene | Tgene | Gene symbol | PRKCE | QPCT | Gene ID | 5581 | 25797 |
| Gene name | protein kinase C epsilon | glutaminyl-peptide cyclotransferase | |
| Synonyms | PKCE|nPKC-epsilon | GCT|QC|sQC | |
| Cytomap | 2p21 | 2p22.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | protein kinase C epsilon type | glutaminyl-peptide cyclotransferaseECglutaminyl cyclaseglutaminyl-tRNA cyclotransferaseglutamyl cyclase | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q02156 | Q16769 | |
| Ensembl transtripts involved in fusion gene | ENST00000306156, ENST00000467135, ENST00000394874, | ENST00000338415, ENST00000537448, | |
| Fusion gene scores | * DoF score | 3 X 4 X 3=36 | 3 X 3 X 3=27 |
| # samples | 5 | 4 | |
| ** MAII score | log2(5/36*10)=0.473931188332412 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(4/27*10)=0.567040592723894 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: PRKCE [Title/Abstract] AND QPCT [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Tumor suppressor gene involved fusion gene, in-frame but not retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PRKCE | GO:0006468 | protein phosphorylation | 18556656 |
| Hgene | PRKCE | GO:0018105 | peptidyl-serine phosphorylation | 15695813 |
| Tgene | QPCT | GO:0017186 | peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase | 21288892 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | PRAD | TCGA-XK-AAJA-01A | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000306156 | ENST00000338415 | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
| 5CDS-intron | ENST00000306156 | ENST00000537448 | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
| intron-3CDS | ENST00000467135 | ENST00000338415 | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
| intron-intron | ENST00000467135 | ENST00000537448 | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
| intron-3CDS | ENST00000394874 | ENST00000338415 | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
| intron-intron | ENST00000394874 | ENST00000537448 | PRKCE | chr2 | 45879587 | + | QPCT | chr2 | 37579932 | + |
Top |
FusionProtFeatures for PRKCE_QPCT |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PRKCE | QPCT |
| Calcium-independent, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that playsessential roles in the regulation of multiple cellular processeslinked to cytoskeletal proteins, such as cell adhesion, motility,migration and cell cycle, functions in neuron growth and ionchannel regulation, and is involved in immune response, cancercell invasion and regulation of apoptosis. Mediates cell adhesionto the extracellular matrix via integrin-dependent signaling, bymediating angiotensin-2-induced activation of integrin beta-1(ITGB1) in cardiac fibroblasts. Phosphorylates MARCKS, whichphosphorylates and activates PTK2/FAK, leading to the spread ofcardiomyocytes. Involved in the control of the directionaltransport of ITGB1 in mesenchymal cells by phosphorylatingvimentin (VIM), an intermediate filament (IF) protein. Inepithelial cells, associates with and phosphorylates keratin-8(KRT8), which induces targeting of desmoplakin at desmosomes andregulates cell-cell contact. Phosphorylates IQGAP1, which binds toCDC42, mediating epithelial cell-cell detachment prior tomigration. In HeLa cells, contributes to hepatocyte growth factor(HGF)-induced cell migration, and in human corneal epithelialcells, plays a critical role in wound healing after activation byHGF. During cytokinesis, forms a complex with YWHAB, which iscrucial for daughter cell separation, and facilitates abscissionby a mechanism which may implicate the regulation of RHOA. Incardiac myocytes, regulates myofilament function and excitationcoupling at the Z-lines, where it is indirectly associated with F-actin via interaction with COPB1. During endothelin-inducedcardiomyocyte hypertrophy, mediates activation of PTK2/FAK, whichis critical for cardiomyocyte survival and regulation of sarcomerelength. Plays a role in the pathogenesis of dilated cardiomyopathyvia persistent phosphorylation of troponin I (TNNI3). Involved innerve growth factor (NFG)-induced neurite outgrowth and neuronmorphological change independently of its kinase activity, byinhibition of RHOA pathway, activation of CDC42 and cytoskeletalrearrangement. May be involved in presynaptic facilitation bymediating phorbol ester-induced synaptic potentiation.Phosphorylates gamma-aminobutyric acid receptor subunit gamma-2(GABRG2), which reduces the response of GABA receptors to ethanoland benzodiazepines and may mediate acute tolerance to theintoxicating effects of ethanol. Upon PMA treatment,phosphorylates the capsaicin- and heat-activated cation channelTRPV1, which is required for bradykinin-induced sensitization ofthe heat response in nociceptive neurons. Is able to form acomplex with PDLIM5 and N-type calcium channel, and may enhancechannel activities and potentiates fast synaptic transmission byphosphorylating the pore-forming alpha subunit CACNA1B (CaV2.2).In prostate cancer cells, interacts with and phosphorylates STAT3,which increases DNA-binding and transcriptional activity of STAT3and seems to be essential for prostate cancer cell invasion.Downstream of TLR4, plays an important role in thelipopolysaccharide (LPS)-induced immune response byphosphorylating and activating TICAM2/TRAM, which in turnactivates the transcription factor IRF3 and subsequent cytokinesproduction. In differentiating erythroid progenitors, is regulatedby EPO and controls the protection against the TNFSF10/TRAIL-mediated apoptosis, via BCL2. May be involved in the regulation ofthe insulin-induced phosphorylation and activation of AKT1.{ECO:0000269|PubMed:11884385, ECO:0000269|PubMed:1374067,ECO:0000269|PubMed:15355962, ECO:0000269|PubMed:16757566,ECO:0000269|PubMed:17603037, ECO:0000269|PubMed:17875639,ECO:0000269|PubMed:17875724}. | Responsible for the biosynthesis of pyroglutamylpeptides. Has a bias against acidic and tryptophan residuesadjacent to the N-terminal glutaminyl residue and a lack ofimportance of chain length after the second residue. Alsocatalyzes N-terminal pyroglutamate formation. In vitro, catalyzespyroglutamate formation of N-terminally truncated form of APPamyloid-beta peptides [Glu-3]-amyloid-beta. May be involved in theN-terminal pyroglutamate formation of several amyloid-relatedplaque-forming peptides. {ECO:0000269|PubMed:15063747,ECO:0000269|PubMed:18486145, ECO:0000269|PubMed:21288892}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | PRKCE | chr2:45879587 | chr2:37579932 | ENST00000306156 | + | 1 | 15 | 1_99 | 116 | 738 | Domain | C2 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | >PRKCE | chr2:45879587 | chr2:37579932 | ENST00000306156 | + | 1 | 15 | 408_668 | 116 | 738 | Domain | Protein kinase |
| Hgene | >PRKCE | chr2:45879587 | chr2:37579932 | ENST00000306156 | + | 1 | 15 | 669_737 | 116 | 738 | Domain | Note=AGC-kinase C-terminal |
| Hgene | >PRKCE | chr2:45879587 | chr2:37579932 | ENST00000306156 | + | 1 | 15 | 414_422 | 116 | 738 | Nucleotide binding | ATP |
| Hgene | >PRKCE | chr2:45879587 | chr2:37579932 | ENST00000306156 | + | 1 | 15 | 169_220 | 116 | 738 | Zinc finger | Phorbol-ester/DAG-type 1 |
| Hgene | >PRKCE | chr2:45879587 | chr2:37579932 | ENST00000306156 | + | 1 | 15 | 242_292 | 116 | 738 | Zinc finger | Phorbol-ester/DAG-type 2 |
Top |
FusionGeneSequence for PRKCE_QPCT |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_PRKCE_ENST00000306156_chr2_45879587_+_QPCT_ENST00000338415_chr2_37579932_+_438aa MVVFNGLLKIKICEAVSLKPTAWSLRHAVGPRPQTFLLDPYIALNVDDSRIGQTATKQKTNSPAWHDEFVTDVCNGRKIELAVFHDAPIG YDDFVANCTIQFEELLQNGSRHFEDWNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVL EIDTFLSQTPYGYRSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQ LIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLL |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_PRKCE_ENST00000306156_chr2_45879587_+_QPCT_ENST00000338415_chr2_37579932_+_1314nt ATGGTAGTGTTCAATGGCCTTCTTAAGATCAAAATCTGCGAGGCCGTGAGCTTGAAGCCCACAGCCTGGTCGCTGCGCCATGCGGTGGGA CCCCGGCCGCAGACTTTCCTTCTCGACCCCTACATTGCCCTCAATGTGGACGACTCGCGCATCGGCCAAACGGCCACCAAGCAGAAGACC AACAGCCCGGCCTGGCACGACGAGTTCGTCACCGATGTGTGCAACGGACGCAAGATCGAGCTGGCTGTCTTTCACGATGCCCCCATAGGC TACGACGACTTCGTGGCCAACTGCACCATCCAGTTTGAGGAGCTGCTGCAGAACGGGAGCCGCCACTTCGAGGACTGGAATTACCACCAG CCAGCCATTTTGAATTCATCGGCTCTTCGGCAAATTGCAGAAGGCACCAGTATCTCTGAAATGTGGCAAAATGACTTACAGCCATTGCTG ATAGAGCGATACCCGGGATCCCCTGGAAGCTATGCTGCTCGTCAGCACATCATGCAGCGAATTCAGAGGCTTCAGGCTGACTGGGTCTTG GAAATAGACACCTTCTTGAGTCAGACACCCTATGGGTACCGGTCTTTCTCAAATATCATCAGCACCCTCAATCCCACTGCTAAACGACAT TTGGTCCTCGCCTGCCACTATGACTCCAAGTATTTTTCCCACTGGAACAACAGAGTGTTTGTAGGAGCCACTGATTCAGCCGTGCCATGT GCAATGATGTTGGAACTTGCTCGTGCCTTAGACAAGAAACTCCTTTCCTTAAAGACTGTTTCAGACTCCAAGCCAGATTTGTCACTCCAG CTGATCTTCTTTGATGGTGAAGAGGCTTTTCTTCACTGGTCTCCTCAAGATTCTCTCTATGGGTCTCGACACTTAGCTGCAAAGATGGCA TCGACCCCGCACCCACCTGGAGCGAGAGGCACCAGCCAACTGCATGGCATGGATTTATTGGTCTTATTGGATTTGATTGGAGCTCCAAAC CCAACGTTTCCCAATTTTTTTCCAAACTCAGCCAGGTGGTTCGAAAGACTTCAAGCAATTGAACATGAACTTCATGAATTGGGTTTGCTC AAGGATCACTCTTTGGAGGGGCGGTATTTCCAGAATTACAGTTATGGAGGTGTGATTCAGGATGACCATATTCCATTTTTAAGAAGAGGT GTTCCAGTTCTGCATCTGATACCGTCTCCTTTCCCTGAAGTCTGGCACACCATGGATGACAATGAAGAAAATTTGGATGAATCAACCATT |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_PRKCE_ENST00000306156_chr2_45879587_+_QPCT_ENST00000338415_chr2_37579932_+_2136nt CAGCCCCCGCGGCTTGCAGCGGAGCCGACAGCTCGTCTTCTCTTCTGGAGGTGCAGCTGGTGGTCGGGGGGAGAGACTTGCTCCAAACAC GGACATCCCCCAGCTCTCCCCCCTCCCTGTTTTCCGTTAGGAACCCGGCGAGGAAATACATGCACTGGCTGAGAATCGCCCGCGCCAGGG CGCAACGCCACAAGGTGTAGGGAGTGTGCGGGGTGGGGCGAAAGGGGACCCAAGAGTCCCTGTGGCTCGGAGTGCCGGGCCGTCGGTTCT TCATTCCTGCCCTCGGGGCAGACGGAGTGACCCCGGCCCCCACTCCCCGCCCCGACCATGGTAGTGTTCAATGGCCTTCTTAAGATCAAA ATCTGCGAGGCCGTGAGCTTGAAGCCCACAGCCTGGTCGCTGCGCCATGCGGTGGGACCCCGGCCGCAGACTTTCCTTCTCGACCCCTAC ATTGCCCTCAATGTGGACGACTCGCGCATCGGCCAAACGGCCACCAAGCAGAAGACCAACAGCCCGGCCTGGCACGACGAGTTCGTCACC GATGTGTGCAACGGACGCAAGATCGAGCTGGCTGTCTTTCACGATGCCCCCATAGGCTACGACGACTTCGTGGCCAACTGCACCATCCAG TTTGAGGAGCTGCTGCAGAACGGGAGCCGCCACTTCGAGGACTGGAATTACCACCAGCCAGCCATTTTGAATTCATCGGCTCTTCGGCAA ATTGCAGAAGGCACCAGTATCTCTGAAATGTGGCAAAATGACTTACAGCCATTGCTGATAGAGCGATACCCGGGATCCCCTGGAAGCTAT GCTGCTCGTCAGCACATCATGCAGCGAATTCAGAGGCTTCAGGCTGACTGGGTCTTGGAAATAGACACCTTCTTGAGTCAGACACCCTAT GGGTACCGGTCTTTCTCAAATATCATCAGCACCCTCAATCCCACTGCTAAACGACATTTGGTCCTCGCCTGCCACTATGACTCCAAGTAT TTTTCCCACTGGAACAACAGAGTGTTTGTAGGAGCCACTGATTCAGCCGTGCCATGTGCAATGATGTTGGAACTTGCTCGTGCCTTAGAC AAGAAACTCCTTTCCTTAAAGACTGTTTCAGACTCCAAGCCAGATTTGTCACTCCAGCTGATCTTCTTTGATGGTGAAGAGGCTTTTCTT CACTGGTCTCCTCAAGATTCTCTCTATGGGTCTCGACACTTAGCTGCAAAGATGGCATCGACCCCGCACCCACCTGGAGCGAGAGGCACC AGCCAACTGCATGGCATGGATTTATTGGTCTTATTGGATTTGATTGGAGCTCCAAACCCAACGTTTCCCAATTTTTTTCCAAACTCAGCC AGGTGGTTCGAAAGACTTCAAGCAATTGAACATGAACTTCATGAATTGGGTTTGCTCAAGGATCACTCTTTGGAGGGGCGGTATTTCCAG AATTACAGTTATGGAGGTGTGATTCAGGATGACCATATTCCATTTTTAAGAAGAGGTGTTCCAGTTCTGCATCTGATACCGTCTCCTTTC CCTGAAGTCTGGCACACCATGGATGACAATGAAGAAAATTTGGATGAATCAACCATTGACAATCTAAACAAAATCCTACAAGTCTTTGTG TTGGAATATCTTCATTTGTAATACTCTGATTTAGTTTAGGATAATTGGTTCTAGAATTGAATTCAAAAGTCAAGGCATCATTTAAAATAA TCTGATTTCAGACAAATGCTGTGTGGAAACATCTATCCTATAGATCATCCTATTCTTATGTGTCTTTGGTTATCAGATCAATTACAGAAT AATTGTGTTGTGATATTGTGTCCTAAATTGCTCATTAATTTTTATTTACAGATTGAAAAAGAGGGACCGTGTAAAGAAAATGGAAAATAA ATATCTTTCAAAGACTCTTTTAGATAAACACGATGAGGCAAAATCAGGTTCATTCATTCAACGATAGTTTCTCAACAGTACTTAAATAGC GGTTGGAAAACGTAGCCTTCATTTTATGATTTTTTCATATGTGGAAATCTATTACATGTAATACAAAACAAACATGTAGTTTGAAGGCGG |
Top |
FusionGenePPI for PRKCE_QPCT |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| PRKCE | RASGRP3, GAD2, GAD1, ADAP1, VDAC1, SLC25A4, HK2, MAPK1, RAF1, GJA1, GNB2L1, CFTR, GNA12, GNA13, MYH9, COPB2, KRT1, ACTA1, YWHAZ, TIAM1, PDLIM5, PIK3CB, AFAP1, KRT8, KRT18, DSP, MAP4K4, STAT1, HSP90AB1, PRKCE, KAT5, HIST1H1A, IBTK, MARK2, PPP1R14A, IKBKB, IKBKG, ITGB2, ATF2, RPS6KB2, BRAF, HSP90AA1, ELAVL1, NUMB, KEAP1, IL32, ZBTB16, NANOG, EGFR, BAD, BCL6 | QPCT | CUL3, CUL4A, CUL4B, CUL5, CUL2, CUL1, COPS5, DCUN1D1, CAND1, NEDD8, DHRS4, NUBP1, FRAS1, ELP3, NUBP2, UBAP2, MED4, MED20, MED23 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PRKCE_QPCT |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for PRKCE_QPCT |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | PRKCE | C0020429 | Hyperalgesia | 3 | CTD_human |
| Hgene | PRKCE | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
| Hgene | PRKCE | C0011853 | Diabetes Mellitus, Experimental | 1 | CTD_human |
| Hgene | PRKCE | C0011881 | Diabetic Nephropathy | 1 | CTD_human |
| Hgene | PRKCE | C0023903 | Liver neoplasms | 1 | CTD_human |
| Hgene | PRKCE | C0027051 | Myocardial Infarction | 1 | CTD_human |
| Hgene | PRKCE | C0031117 | Peripheral Neuropathy | 1 | CTD_human |
| Hgene | PRKCE | C0151744 | Myocardial Ischemia | 1 | CTD_human |
| Hgene | PRKCE | C0236969 | Substance-Related Disorders | 1 | CTD_human |
| Hgene | PRKCE | C0242231 | Coronary Stenosis | 1 | CTD_human |
| Hgene | PRKCE | C0878544 | Cardiomyopathies | 1 | CTD_human |
| Tgene | QPCT | C0023434 | Chronic Lymphocytic Leukemia | 1 | CTD_human |
| Tgene | QPCT | C0025202 | melanoma | 1 | CTD_human |
| Tgene | QPCT | C0162820 | Dermatitis, Allergic Contact | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|